rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

William J. Link

Director

Company insider

Files Form 4 as: Director, Tarsus Pharmaceuticals; Director and 10% owner, RxSight; Director, Lensar; Director and 10% owner, Oyster Point Pharma; Director and 10% owner, Glaukos; Director, Edwards Lifesciences; Director and 10% owner, Vivani Medical; Director and 10% owner, Inogen.

Every Form 4 they filed

In numbers

Trades disclosed
363
Buys
3
Sells
20
Bought
$940K
Sold
$40.9M
Companies
11
Companies where not an officer
11
First trade
5 Jan 2006
Last trade
15 Sep 2026
Last filed
17 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
TARS Tarsus PharmaceuticalsDirector · Biotechnology · last 15 Sep 20260 buys · 6 sells
RXST RxSightDirector, 10% owner · Medical Devices · last 17 Jun 20261 buy · 1 sell
LNSR LensarDirector · Medical Devices · last 3 Jun 20260 buys · 0 sells
Oyster Point PharmaDirector, 10% owner · last 5 Jan 20221 buy · 1 sell
GKOS GlaukosDirector, 10% owner · Medical Devices · last 3 Jun 20210 buys · 5 sells
EW Edwards LifesciencesDirector · Medical Devices · last 8 May 20200 buys · 5 sells
VANI Vivani MedicalDirector, 10% owner · Medical Devices · last 4 Jun 20190 buys · 0 sells
INGN InogenDirector, 10% owner · Medical Devices · last 18 Dec 20140 buys · 0 sells
Abbott Medical OpticsDirector · last 26 Feb 20090 buys · 0 sells
IntralaseDirector, 10% owner · last 2 Apr 20070 buys · 2 sells
Novacea10% owner · last 15 May 20061 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Sep 2026filed 17 Sep 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Code M—201filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Sold$915K11,675 at $78.33filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Sold$60K759 at $79.00filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—201 at $0.00filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Sold$5,28166 at $80.01filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—201 at $0.00filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Code M—201filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Sold$915K11,675 at $78.33filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Sold$60K759 at $79.00filing
15 Sep 2026filed 17 Sep 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Sold$5,28166 at $80.01filing
25 Jun 2026filed 29 Jun 2026TARS Tarsus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—3,837 at $0.00filing
25 Jun 2026filed 29 Jun 2026TARS Tarsus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—2,417 at $0.00filing
25 Jun 2026filed 29 Jun 2026TARS Tarsus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—806 at $0.00filing
25 Jun 2026filed 29 Jun 2026TARS Tarsus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—3,837 at $0.00filing
25 Jun 2026filed 29 Jun 2026TARS Tarsus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—2,417 at $0.00filing
25 Jun 2026filed 29 Jun 2026TARS Tarsus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—806 at $0.00filing
17 Jun 2026filed 18 Jun 2026RXST RxSightMedical DevicesSEC FORM 4 Code A—37,037filing
17 Jun 2026filed 18 Jun 2026RXST RxSightMedical DevicesSEC FORM 4 Code A—37,037filing
15 Jun 2026filed 17 Jun 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Sold$655K10,572 at $61.97filing
15 Jun 2026filed 17 Jun 2026TARS Tarsus PharmaceuticalsBiotechnologySEC FORM 4 Sold$121K1,928 at $62.94filing

News

Reviewing Tarsus Pharmaceuticals (NASDAQ:TARS) and Novo Nordisk A/S (NYSE:NVO)TARS · themarketsdaily.com · 10 Oct 2026Astrazeneca (NYSE:AZN) and Tarsus Pharmaceuticals (NASDAQ:TARS) Financial ReviewTARS · dailypolitical.com · 6 Oct 2026

0 headlines in the last 90 days name William J. Link; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care18
Not placed5

Buys in green, sells in red, by the company’s sector.

Related people

David E. I. PyottDirector · Director at Tarsus Pharmaceuticals, filing Form 4 there in the last year
Wendy L. YarnoDirector · Director at Tarsus Pharmaceuticals, filing Form 4 there in the last year
Eric WeinbergOfficer · Insider at RxSight, filing Form 4 there in the last year
Mark WilterdingChief Financial Officer · Chief Financial Officer at RxSight, filing Form 4 there in the last year
Ronald M. KurtzChief Medical Officer · Chief Medical Officer at RxSight, filing Form 4 there in the last year
Daniel J. LippisCvp, Tavr · Also traded EW in the last 90 days
Tomas NavratilChief Development Officer · Also traded GKOS in the last 90 days
Bobak R. AzamianPresident/CEO and Board Chair · Also traded TARS in the last 90 days